Gallium

• Feb 1, 1979NDANDA018058Curium
• Aug 21, 2019NDANDA210828Uihc Pet Imaging
• Dec 1, 2020NDANDA212642Univ Ca Los Angeles
• Dec 1, 2020NDANDA212643Univ Of Ca San Fran
• Dec 17, 2021NDANDA214032Telix
• Mar 23, 2022NDANDA215841Novartis
• May 14, 2026ANDAANDA219189Ionetix

1. 1Injection Site Pain12830%
2. 2Hot Flush337.8%
3. 3Erectile Dysfunction255.9%
4. 4Fatigue174.0%
5. 5Death112.6%
6. 6Burning Sensation92.1%
7. 7Muscular Weakness92.1%
8. 8Overdose92.1%
9. 9Pathological Fracture92.1%
10. 10Rash92.1%
11. 11Asthenia81.9%
12. 12Injection Site Discomfort81.9%
13. 13Positron Emission Tomogram Abnormal81.9%
14. 14Anaemia71.7%
15. 15Cerebral Amyloid Angiopathy71.7%

Recent PubMed references pinned to Gallium as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Gallium Protoporphyrin and Lipid Crystalline Nanoparticles Promote the Activity of Ampicillin against MRSA.
  ACS infectious diseases · 2026 · Awad M, Feizi S, Wormald PJ, et al.
  PMID 42207859DOI 10.1021/acsinfecdis.6c00202
• Establishment of (68)Ga-DOTA-Based Pretargeted Radioimmunodiagnosis.
  Molecular pharmaceutics · 2026 · Veach DR, Burnes Vargas D, Islam B, et al.
  PMID 42151769DOI 10.1021/acs.molpharmaceut.5c01766
• Preclinical characterization of a novel FAP-targeted PET tracer, [(68)Ga]Ga-CB6NT-FAPI.
  Nuclear medicine and biology · 2026 · Seo HY, Kim HS, Yoo RJ, et al.
  PMID 42119447DOI 10.1016/j.nucmedbio.2026.109632
• Specific imaging of bacterial infection: a translational approach using positron emission tomography and gallium-68-labeled maltohexaose.
  Theranostics · 2026 · Wegener SM, Weiberg D, Thackeray JT, et al.
  PMID 42094617DOI 10.7150/thno.125904
• Novel Covalent FAP-Targeted [(68)Ga]Ga-DOTA-mFS-KERERG-FAP-2286 for Improved Pharmacokinetics and Enhanced Tumor Uptake.
  Molecular pharmaceutics · 2026 · Jin Z, Wu T, Tang S, et al.
  PMID 42052981DOI 10.1021/acs.molpharmaceut.6c00249
• Interaction of bi-nuclear gallium(III) complexes with human serum albumin and impact on potency towards osteosarcoma stem cells.
  Dalton transactions (Cambridge, England : 2003) · 2026 · Feng X, Suntharalingam K
  PMID 42023658DOI 10.1039/d6dt00591h
• The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.
  The Prostate · 2026 · Kıkılı Cİ, Kapar C, Yağmur FH, et al.
  PMID 42018584DOI 10.1002/pros.70185
• Toward circular Gallium: Recovery pathways from Bayer Liquor, red Mud, fly Ash, and e-waste.
  Waste management (New York, N.Y.) · 2026 · Zhang X, Zhang Z, Fu J, et al.
  PMID 42008918DOI 10.1016/j.wasman.2026.115543

The 10 most recently updated of 332 ClinicalTrials.gov registrations naming Gallium as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
  Recruiting · Phase 2 · Interventional · 80 enrolled · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  NCT02019706updated 2026-06-12
• [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
  Recruiting · Phase 1 · Interventional · 120 enrolled · National Cancer Institute (NCI)
  NCT06479811updated 2026-06-12
• Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
  Completed · Phase 3 · Interventional · 69 enrolled · Jiangsu HengRui Medicine Co., Ltd.
  NCT06091748updated 2026-06-12
• Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
  Recruiting · Phase 1 · Interventional · 42 enrolled · Weill Medical College of Cornell University
  NCT04886986updated 2026-06-11
• NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
  Active not recruiting · Phase 1 · Interventional · 31 enrolled · Novartis Pharmaceuticals
  NCT06379217updated 2026-06-10
• A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
  Recruiting · Phase 1 · Phase 2 · Interventional · 58 enrolled · Novartis Pharmaceuticals
  NCT06247995updated 2026-06-10
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  Recruiting · Phase 3 · Interventional · 450 enrolled · Novartis Pharmaceuticals
  NCT05939414updated 2026-06-10
• A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
  Recruiting · Phase 1 · Interventional · 36 enrolled · Novartis Pharmaceuticals
  NCT07117214updated 2026-06-09
• PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
  Completed · Phase 1 · Interventional · 20 enrolled · University Hospital, Bordeaux
  NCT02134639updated 2026-06-09
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
  Active not recruiting · Phase 3 · Interventional · 1,140 enrolled · Novartis Pharmaceuticals
  NCT04720157updated 2026-06-08

Frequently asked questions

What are the brand names for Gallium?

Gallium is marketed under brand names including Ganite.